Ala Ali

#Nephrologist & #Transplant Physician #Education @TTS, and #ISNWCN #Italy 🇮🇹 #Coffee ☕️

[Hypertension @HyperAHA]

REVIEW: Angiotensinogen Reconsidered: Evolving Perspectives in Hypertension Research

https://t.co/jcfxxiejrS

[NDT @NDTsocial]

🆕 Review:

Infection risk mitigation with complement inhibitors in kidney disease

https://t.co/O6UcqLJQdQ

[Leonardo V. Riella @LVRiella]

Great renal grand rounds @MGBKidneys Ritu Seethapathy discussing rare entity of podocyte infolding glomerulopathy(PIG) after kidney #transplantation in patient w/ lupus. PIG is a morphologic manifestation of chronic podocyte injury &interferon-driven immune dysregulation @AlJurdi

[Transplantation @TransplantJrnl]

@WTC2025 congress showcased innovation that is shaping the future of beta-cell replacement therapy. Pancreas and islet transplantation continue to advance rapidly, with major progress in organ preservation, immunosuppression, and regenerative therapies. https://t.co/tAWqOJqIaZ

[Nature Reviews Nephrology @NatRevNeph]

Gene–disease relationships for glomerular phenotypes: expert recommendations from ClinGen https://t.co/1mKtdYLrX7

[Ala Ali @alanephro]

@Kdhchels_ If this is true, why Pedro Neto? Alonso should learn from RM lessons. He should not be preoccupied; he should assess first and then make a wise decision.

[GlomCon Arabia @glomconarabia]

Don’t miss this timely seminar today!
One correction- Lecture will start at 7pm Egypt time (equivalent to 7 pm KSA and Kuwait time, 8 pm UAE time).
The rest of the timezones below (besides Egypt) is correct.
Thank you for your patience.
@GlomCon

[Sanjeev Sethi @SethiRenalPath]

Difficult but good recent teaching case.

LM- normal appearing glomeruli but proximal tubules filled with eosinophilic granules.

IF- negative.

EM- large number of lysosomes, with degenerative changes.

Lysozyme stain 3+ positive in proximal tubules.

Dx: Lysozyme associated-tubulopathy (myelofibrosis/clinical).

Usually see this in patients with CML.

D/D: light chain proximal tubulopathy, but IF & pronase IF are negative.

60-yr old with chronic kidney disease, pulmonary nodules, and JAK2+ myelofibrosis.

Evaluation showed high levels of serum lysozyme, and lysozymuria.

[James Myers @JamesMy56782210]

Differentiating the Trio of Focal Segmental Glomerulosclerosis Causes - MedPage Today - https://t.co/WFpcjecuGa #GoogleAlerts

[Jen Li @JLi_Renal]

@ttsorg webinar for clinically relevant information useful for all transplant physicians

https://t.co/UKOnPlfvGp

@KottonNelson @HumarAtul @HansHHirsch1

[Tobias B. Huber @Tobias_B_Huber]

"Anti-nephrin antibodies in pediatric nephrotic syndrome: a new paradigm" (via #pubmedontap) https://t.co/zKqr0Js3Go

[NDT @NDTsocial]

Immune checkpoint inhibitor–associated nephritis—treatment standard

🆓https://t.co/rKsGiIOmbV

[Ala Ali @alanephro]

@LegacySiu Alvaro Morara

[Sanjeev Sethi @SethiRenalPath]

Methamphetamine abuse=severe thrombotic microangiopathy

Unfortunate weekend case 😢

Glomeruli: mesangiolysis +++ & ischemic changes
Interstitium: Hemorrhage, inflammation & scarring
Vessels: Severe sclerosis, thrombosis, schistocytes

40-yr woman, hypertension, AKI, meth abuse

[GlomCon @GlomCon]

🚨 Update Alert 👉 Immune Complex-Mediated Glomerulonephritis at https://t.co/S5Vy4yyvlg

ICGN represents a broad diagnostic umbrella. This dives into the heterogeneous etiologies characterized by granular immunoglobulin and complement deposition.

#GlomCon #Pathology #ICGN

[Ala Ali @alanephro]

What a great paper by Professor @SethiRenalPath on "Finding the etiology of MPGN" in @Kidney_Int. It emphasizes the growing understanding of this GN pattern and paves the way for more personalized therapy.
https://t.co/sEKRs7rmxt
Summary

[GlomCon Arabia @glomconarabia]

Join us tomorrow, April 10, 2026, on a knowledge rollercoaster road to the understanding of Targeted Therapy for C3GN by @GlomerGal

Join meeting here: https://t.co/kIt15Z5NeQ
Meeting ID: 884 4208 1901
Passcode: 100499 Visit us 👉https://t.co/9rPnSqpQR6

@GlomCon

[AJKD @AJKDonline]

A Young Man With Nephrotic Syndrome and Facial Rash: A Quiz

https://t.co/GawXOnByGx (FREE)

•What further tests are needed to determine the etiology of the rash?
•What additional tests can be done?
•How would you treat this patient?

[CME INDIA @CMEINDIA1]

Dapagliflozin is not dialyzable and does not accumulate significantly in dialysis patients—supporting biological plausibility for safe use.

CME INDIA Clinical Pearls: SGLT2 Inhibitors in Dialysis (HD & PD)

▪️Evidence Gap Alert:
While SGLT2 inhibitors robustly reduce CKD progression, CV events, and mortality in non-dialysis CKD, patients on dialysis (HD/PD) were excluded from all landmark RCTs, creating a major evidence void.

▪️Mechanistic Shift in ESKD:
In dialysis patients, classical glucosuric/tubular effects are minimal due to low nephron mass; benefits are likely mediated via cardio-metabolic off-target pathways (↓ inflammation, ↓ oxidative stress, improved myocardial energetics).

▪️Pharmacokinetic Reassurance: Dapagliflozin is not dialyzable and does not accumulate significantly in dialysis patients—supporting biological plausibility for safe use.

▪️Signal from Early Data:
Small trials and observational cohorts suggest potential CV benefit, improved volume status, and preservation of residual kidney function, particularly in incremental dialysis—without major safety signals.

▪️Peritoneal Dialysis Uncertainty:
In PD, evidence is sparse and inconsistent—some studies show ↑ ultrafiltration and ↓ BP, while others show no effect on peritoneal glucose transport.

▪️Real-World Cohort Insight:
Retrospective analyses indicate lower CV events and mortality in dialysis patients using SGLT2i, but these are hypothesis-generating, not definitive.

▪️Safety Perspective:
No major red flags so far, but risk of volume depletion, hypotension, and rare euglycemic ketoacidosis warrants cautious patient selection.

▪️Clinical Position Today:
Routine use in dialysis cannot be recommended yet; use should be individualized and preferably within research settings or expert supervision.

▪️Future Direction:
Ongoing large RCTs are critical to define efficacy, safety, and patient selection—this could expand SGLT2i use into ESKD therapeutics beyond glycemia.

💢Take-Home Message:
👉 SGLT2 inhibitors in dialysis represent a promising but unproven frontier—mechanistically attractive, observationally encouraging, but awaiting definitive trial evidence before mainstream adoption.

https://t.co/wQHmRxBw6Q

[Kelly Haughton, MD @kidneydoctorpa]

IgA nephropathy progresses to kidney failure in up to 50% of patients within 10–20 years.

On March 29th, the NEJM published the final 24-month data from APPLAUSE-IgAN and the results change the treatment landscape.

Here’s what every nephrologist needs to know 🧵

Barratt J et al. NEJM 2026. DOI: 10.1056/NEJMoa2600743